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There is evidence for strong functional antagonistic
interactions between adenosine A2A receptors (A2ARs)
and dopamine D2 receptors (D2Rs). Although a close
physical interaction between both receptors has re-
cently been shown using co-immunoprecipitation and
co-localization assays, the existence of a A2AR-D2R pro-
tein-protein interaction still had to be demonstrated in
intact living cells. In the present work, fluorescence res-
onance energy transfer (FRET) and bioluminescence res-
onance energy transfer (BRET) techniques were used to
confirm the occurrence of A2AR-D2R interactions in co-
transfected cells. The degree of A2AR-D2R heteromeriza-
tion, measured by BRET, did not vary after receptor acti-
vation with selective agonists, alone or in combination.
BRET competition experiments were performed using a
chimeric D2R-D1R in which helices 5 and 6, the third
intracellular loop (I3), and the third extracellular loop
(E3) of the D2R were replaced by those of the dopamine D1
receptor (D1R). Although the wild type D2R was able to
decrease the BRET signal, the chimera failed to achieve
any effect. This suggests that the helix 5-I3-helix 6-E3 por-
tion of D2R holds the site(s) for interaction with A2AR.
Modeling of A2AR and D2R using a modified rhodopsin
template followed by molecular dynamics and docking
simulations gave essentially two different possible modes
of interaction between D2R and A2AR. In the most prob-
able one, helix 5 and/or helix 6 and the N-terminal por-
tion of I3 from D2R approached helix 4 and the C-termi-
nal portion of the C-tail from the A2AR, respectively.
Heptaspanning membrane receptors (HSMRs)1 or G protein-
coupled receptors (GPCRs) were initially considered mono-
meric proteins that only interact with G proteins. However, it
has become clear that HSMRs are oligomeric structures formed
by receptor homodimers, heterodimers, and multimers and a
variety of proteins interacting at the plane of the membrane
(horizontal level) or across the plane of the membrane (vertical
level) (1–6). Current investigation of these macromolecular
complexes offers great potential for functional proteomics and
offers deeper insight into information handling at the cellular
level. The occurrence of oligomeric complexes involving GPCRs
and intracellular and extracellular proteins indicates that con-
formational changes in response to ligand binding to a receptor
may be transmitted to other protein molecules within the mul-
timolecular complex. The conformational changes transmitted
by direct protein-protein interactions constitute a first level of
regulation of a receptor (6). Heteromeric complexes are not
distributed randomly in the membrane and form clusters fol-
lowing agonist-induced activation. The intercommunication be-
tween heteromeric receptor complexes within clusters repre-
sents a second level of regulation (6). It should also be
considered that the plasma membrane is not an isomorphic
structure, but a structure made by patches with various chem-
ical-physical characteristics (e.g. lipid rafts). Therefore, mul-
timeric complexes and agonist-induced clusters may follow
preferential routes (owing, for example, to the low viscosity of
the membrane) to make contact in the membrane or may be
kept as isolated multimeric complexes or clusters within a
patch (6).
An example of intercommunicating receptors is that formed
by adenosine A2A receptors (A2ARs) and dopamine D2 receptors
(D2Rs). Important experimental evidence has accumulated in
relation to the existence of functional interactions between
A2ARs and D2Rs in the basal ganglia (5, 7, 8). These two
receptors are specifically localized in one subtype of neurons,
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the striatopallidal -aminobutyric acid (GABA)-containing
neurons, on which both receptors express their highest density
in the brain. The striatopallidal GABAergic neurons play a key
role in the pathophysiology of basal ganglia disorders, includ-
ing Parkinson’s disease, and it is a common pathway for the
rewarding effects in drug abuse, as well as the antipsychotic
effects of neuroleptics. Relationships between A2AR and D2R
have been demonstrated at the biochemical, functional, and
behavioral levels, where it has been suggested that the aden-
osine/dopamine cross-talk in the central nervous system may
provide new therapeutic approaches for Parkinson’s disease,
schizophrenia and drug addiction (5, 7, 8). At the biochemical
level, two kinds of antagonistic A2AR-D2R interaction have
been discovered, which can explain the A2AR-D2R interaction
observed at both the functional and behavioral levels. In the
first place, by means of their intramembrane interaction, the
stimulation of A2AR decreases the affinity of D2R for agonists
(9). Second, the stimulation of D2R, a Gi/o protein-coupled re-
ceptor, inhibits cAMP accumulation induced by the stimulation
of the Gs/olf protein-coupled A2AR (10). The intramembrane
A2AR-D2R interaction implies a close physical interaction be-
tween the two receptors. In fact, the pharmacology of D2R is
affected by adenosine analogs activating A2AR. Also, co-immu-
noprecipitation, co-aggregation, and co-internalization of A2AR
and D2R have been recently reported in co-transfected cell lines
(10). The existence of a heterologous, i.e. D2R-mediated, desen-
sitization of A2AR (10) is further evidence of the A2AR-D2R
cross-talk. However, the demonstration of protein-protein in-
teractions between both receptors in living cells remains to be
demonstrated. In the present study, A2AR-D2R heterodimeriza-
tion in a heterologous mammalian expression system has been
investigated by both fluorescence resonance energy transfer
(FRET) and bioluminescence resonance energy transfer
(BRET). The influence of receptor density and agonist binding
on the degree of A2AR-D2R heteromerization was assessed. The
results indicate that the two receptors heteromerize and that
changes in heteromerization do not occur in response to ago-
nists. Based on the results of biochemical, biophysical, and
computational experiments, insights have been gained into
A2AR-D2R heterodimer interface.
EXPERIMENTAL PROCEDURES
Cell Lines—HEK-293T cells (American Type Tissue Culture, Man-
assas, VA) were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 2 mM L-glutamine, 100 units/ml penicillin/streptomycin,
and 10% (v/v) fetal bovine serum (FBS) at 37 °C and in an atmosphere
of 5% CO2. Cells were passaged when they were 80–90% confluent. All
cell culture reagents were from Invitrogen.
Expression Vectors—The human cDNA for Flag-A2AR without its
stop codon was amplified using sense and antisense primers harboring
unique EcoRI and BamHI sites. The fragment then was subcloned to be
in-frame with either Rluc or EYFP into the EcoRI and BamHI restric-
tion site of a Renilla luciferase-expressing vector (pcDNA3.1-Rluc) or
the enhanced yellow variant of GFP (pEYFP-N1; Clontech, Heidelberg,
Germany), respectively, to give the two plasmids, pA2AR-Rluc and
pA2AR-EYFP, that express Rluc or EYFP on the C-terminal ends of the
receptor. The human D2LR was also cloned in the pGFP2-N3(h) and
pEYFP-N1 vectors in a similar fashion, however, subcloned into the
EcoRI and KpnI site of each respective vector to be in-frame with the
GFP fluorescent protein variants, GFP2 and EYFP, respectively. The
previously characterized chimeric D2R-D1R, in which helices 5 and 6
and third intracellular (I3) and third extracellular (E3) loops of the D2R
have been swapped by the corresponding sequence from the D1R, was
described previously (11). The positive control vector used for the FRET
experiments, pGFP2-EYFP, was a gift from the laboratory of R. Pep-
perkok (EMBL, Heidelberg, Germany) (described in Ref. 12).
Transient Transfections—HEK-293T cells growing on coverslips in
6-well dishes were transiently transfected with 10 g of DNA encoding
the indicated proteins by calcium phosphate precipitation (13). For
FRET experiments the LipofectAMINE transfection reagent, FuGENE
6TM (Roche Molecular Biochemicals), was utilized following the product
protocol. In both cases and to maintain the ratio of DNA in co-trans-
fections, the empty vector, pcDNA3.1, was used to equilibrate the
amount of total DNA transfected. 24 h after transfection, the medium
was replaced and cells were then cultured in the same medium until
harvested 32, 48, or 72 h after transfection. For FRET experiments cells
were fixed with a 3.5% paraformaldehyde solution in PBS for 15 min at
room temperature, before washing in PBS and mounting onto slides.
cAMP Determination—The accumulation of cAMP was measured by
a [3H]cAMP assay system (Amersham Biosciences) as described in the
manual from the manufacturer. Transfected HEK-293 cells (2  106
cells/sample) were serum-starved, preincubated with 50 mM Ro 20-
1724, a phosphodiesterase inhibitor (Calbiochem, St. Diego, CA) for 10
min, and then stimulated with the indicated concentrations of agonists,
CGS21680 (A2AR), quinpirole (D2R), and forskolin (all from Sigma), for
15 min prior to the determination of cAMP levels.
FRET-based Acceptor Photo-bleaching Experiments Analyzed by
Confocal Microscopy—Transiently transfected HEK-293T cells were
plated onto 15-mm glass coverslips and mounted onto slides using
Mowiol mounting medium. Confocal laser scanning microscopy was
performed using a Leica SP2 microscope (Leica Microsystems, Mann-
heim, Germany) equipped with an acousto-optical beamsplitter, a 100-
milliwatt argon laser for excitation at 514 nm, and a 20-milliwatt blue
diode laser for excitation at 405 nm. GFP2 was excited with the 405 nm
laser, YFP was excited with the 514 nm laser, and images were ac-
quired in the following sequence. (i) A pre-photo-bleach YFP (acceptor)
image was acquired by scanning while exciting with the 514 nm laser
line. (ii) A pre-photo-bleach GFP2 (donor) image was acquired by scan-
ning while exciting with 405 nm laser line. (iii) A region of interest was
selected and the acceptor (YFP) was subsequently photo-bleached by
scanning repeatedly with the 514 nm laser line until fluorescence
signals were at background levels. (iv) A post-photo-bleach image for
GFP2 was acquired by scanning with the 405 nm laser line. (v) a second
post-photo-bleach image for EYFP was acquired by scanning with the
514 nm laser. In all cases, the spectral imaging was obtained at three
fluorescence detection channels (Ch) set to the following ranges: Ch 1:
490–510 nm, Ch 2: 520–540 nm, Ch 3: 545–565 nm. Settings for gain
and offset of the detectors were identical for all experiments to keep the
relative contribution of the fluorophores to the detection channels con-
stant for spectral un-mixing (see below). The contributions of the GFP
variants, GFP2 and YFP, to each of the three detection channels (spec-
tral signature) were measured in experiments with cells expressing
only one of these proteins and normalized to the sum of the signal
obtained in the three detection channels
FRET Experiments Analyzed by Fluorimetry—Forty-eight hours af-
ter transfection, cells were rapidly washed twice in PBS, detached, and
resuspended in the same buffer. To control the number of cells, the
protein concentration of the samples was determined using a Bradford
assay kit (Bio-Rad) using bovine serum albumin dilutions as standards.
Cell suspension (20 g of protein) was distributed in duplicate into
96-well microplates (black plates with a transparent bottom). Plates
were read in a Fluostar Optima Fluorimeter (BMG Labtechnologies,
Offenburg, Germany) equipped with a high energy xenon flash lamp,
using a 10-nm bandwidth excitation filter at 400 nm (393–403 nm), and
10-nm bandwidth emission filters corresponding to 506–515 nm filter
(Ch 1) and 527–536 nm filter (Ch 2). Gain settings were identical for all
experiments to keep the relative contribution of the fluorophores to the
detection channels constant for spectral un-mixing. The contributions
of the GFP variants, GFP2 and YFP proteins alone, to the two detection
channels (spectral signature) were measured in experiments with cells
expressing only one of these proteins and normalized to the sum of the
signal obtained in the two detection channels. The spectral signatures
of the different receptors fused to either GFP2 or YFP did not signifi-
cantly vary from the determined spectral signatures of the fluorescent
proteins alone.
Quantitation of FRET—Linear un-mixing was done as described by
Zimmermann et al. (12) to separate the two emission spectra. To deter-
mine the fluorescence emitted by each of two individual fluorophores
(FluoA corresponding to the donor and FluoB corresponding to the
acceptor) in FRET experiments analyzed by confocal microscopy, the




























where Chx and Chy represent the signals in detection channels x and y,
and Ax, Bx and Ay, By represent the normalized contributions of FluoA
or FluoB to channels x and y, as they are known from the spectral
signatures of the fluorescent proteins. For the fluorimetric experiments,
the same equations were applied. By these equations the fluorophore
signals, FluoA and FluoB, were calculated using the processing rou-
tines written (and generously provided) by T. Zimmermann (EMBL,
Heidelberg, Germany) in Interactive Data Language (IDL, Research
Systems Inc., Boulder, CO).
According to Zimmermann et al. (12), apparent FRET efficiencies EA
in acceptor photo-bleaching experiments were calculated for each pixel
i according to Equation 5.





FD represents the emitted donor fluorescence (FluoA) before and Fpb
D
after photo-bleaching of the acceptor. For the fluorimetric experiments,
FRET efficiency was calculated as direct sensitization of the acceptor
corresponding to acceptor fluorescence (FluoB) after excitation at
400 nm.
BRET Experiments—Forty-eight hours after transfection, cells were
rapidly washed twice in PBS, detached, and resuspended in the same
buffer. To control the number of cells, sample protein concentration was
determined using a Bradford assay kit (Bio-Rad, Munich, Germany)
using bovine serum albumin dilutions as standards. To quantify A2AR-
Rluc and D2-YFP expression, cell suspension (20 g of protein) was
distributed in duplicate into 96-well microplates (Corning 3604, white
plates with transparent bottom). The fluorescence was measured using
a Packard FluoroCountTM with an excitation filter of 485 nm and an
emission filter of 530 nm using the following parameters: gain of 1,
photomultiplier fixed at 1100 V, and read time of 1 s. Fluorescence was
quantified as in-fold over the background (mock-transfected cells). The
same samples were incubated for 10 min with 5 M coelenterazine H
(Molecular Probes, Eugene, OR), and the luminescence was measured
using a Packard LumiCountTM with the following parameters: gain of 1,
photomultiplier fixed at 700 V, and a read time of 1 s. For BRET
measurement, 20 g of cell suspension were distributed in duplicates in
96-well microplates (Corning 3600, white opaque plates) and 5 M
coelenterazine H was added. After 1 min the readings were collected
using a Fusion microplate analyzer (Packard, Meriden, CT) that allows
the integration of the signals detected in the 440–500- and the 510–
590-nm windows using filters with the appropriate band pass. The
BRET ratio is defined as [(emission at 510–590)/(emission at 440–500)]
 Cf where Cf corresponds to (emission at 510–590)/(emission at 440–
500) for the -Rluc construct expressed alone in the same experiment.
Subcellular Membrane Isolation—HEK-293T cells transiently co-
transfected with the A2AR-Rluc and D2RYFP were grown in 100-mm
dishes to 80–90% confluence. Cells were washed twice with ice-cold
PBS and lysed with 2 ml of ice-cold hypotonic lysis buffer (20 mM
HEPES, pH 7.4, 2 mM EDTA, 2 mM EGTA, 6 mM MgCl2, 1 mM phenyl-
methylsulfonyl fluoride, and 1:100 dilution of a protease inhibitor mix-
ture). Lysate was then sonicated for 30 s, (3 strokes with 1-min delay
between strokes) followed by two 10-s bursts in a Polytron tissue
grinder. Cellular debris and unlysed cells were removed by centrifuging
at 1500 rpm for 5 min at 4 °C. Sucrose was added to achieve a final
concentration of 0.2 M, and 2 ml were applied to the top of a discontin-
uous step gradient (5 ml/step) made at 0.5, 0.9, 1.2, 1.35, 1.5, and 2.0 M
sucrose in lysis buffer. The samples were then centrifuged for 16 h at
27,000 rpm at 4 °C in a Beckman SW28 rotor. The plasma membrane
was recovered in the sucrose gradient at the interface between 0.5 and
0.9 M. The endoplasmic reticular membrane samples were recovered at
the interface between 1.35 and 1.5 M, and luminescence was detected.
For the verification of isolated membranes as either plasma or endo-
plasmic reticulum membranes, fractions were then precipitated with
cold acetone overnight and analyzed by Western blotting using mono-
clonal antibodies against NaK-ATPase pump (1:250 dilution, Sigma)
and calnexin (1:500 dilution, BD Transduction Laboratories).
Raft Disruption—HEK-293T cells were serum-starved overnight
24 h after transfection. Cholesterol depletion was achieved by incuba-
tion for 1 h at 37 °C with 2% 2-hydroxypropyl--cyclodextrin (-CD,
Sigma) in Dulbecco’s modified Eagle’s medium. Cholesterol repletion
was done, after washing twice with fresh medium, by incubation for 1 h
at 37 °C with 0.4% -CD and 16 mg/ml cholesterol (Sigma). Complete
raft disruption was assessed as caveolin-1 displacement in a discontin-
uous sucrose gradient. For this, confluent control or depleted cells were
washed twice with ice-cold PBS, scraped, and resuspended into 2 ml of
500 mM Na2CO3, pH 11.0. Cells were sequentially homogenized using a
Polytron (3 times, 10 s), a syringe (20 times) and a sonicator (3 times,
30 s), placed at the bottom of an ultracentrifuge tube and adjusted to
45% sucrose in Mes-buffered saline (25 mM Mes, 0,15 M NaCl, pH 6.5).
A discontinuous 5–35% sucrose gradient was formed above in Mes-
buffered saline containing 250 mM Na2CO3, pH 6.5. After centrifugation
at 105,000  g for 18 h at 4 °C in a SW41.Ti rotor (Beckman), fractions
were collected and analyzed by Western blot using an antibody against
caveolin-1 (BD Transduction Laboratories, Lexington, KY). -CD ef-
fects were also tested by mitogen-activated protein kinase phosphoryl-
ation analysis; treated cells were directly resuspended in loading buffer
and analyzed by Western blot using the antibodies against phosphoryl-
ated or total extracellular signal-regulated kinase-1/2 (Sigma).
Three-dimensional Model Building of the Human D2R and Human
A2AR—For the D2R, the whole sequence of the human short variance
(SWISS-PROT entry P14416) was modeled. The intracellular loops 1, 2,
and 3 and the extracellular loops 1, 2, and 3 will be, respectively,
abbreviated as I1, I2, I3, E1, E2, and E3. Building of I3 (sequence
215–334) was carried out by comparative modeling (by means of MOD-
ELER; Ref. 14) by using the domain A2 of Glycyl-TRNA synthetase
(PDB entry 1ati; sequence 393–505) as a template, according to the
results of fold recognition by means of THREADER (15). This template,
characterized by a three-layer () sandwich architecture and a Ross-
mann fold, resulted to be the top hit, holding a reliable z-score (i.e. 3.65).
Indeed, secondary structure predictions made by four different methods
agree acceptably well with the secondary structures computed on the I3
in the selected average minimized structure of D2R. Similarly, E2 was
separately obtained by Molecular Dynamics simulations. A chimeric
rhodopsin template (PDB entry 1F88; Ref. 16) was built by introducing
the E2 and I3 models after deleting the rhodopsin segments 176–201,
229–235, and 240–243. This template was employed to generate 25
different models of the D2R according to the sequence alignment shown
in Fig. 11 (available as supplementary material in the on-line version of
this article). Among these models, the one showing the lowest degree of
violation of the structural restraints was used to generate the input
structures for Molecular Dynamics simulations. Automatic rotation of
the side chains when in bad conformation was performed, leading to
different input arrangements. These arrangements were subjected to
energy minimization and 150-ps runs of Molecular Dynamics simula-
tions, by means of the program CHARMM (17). Minimizations were
carried out by using 1500 steps of steepest descent followed by a con-
jugate gradient minimization, until the root mean square gradient was
less than 0.001 kcal/mol Å. A distance dependent dielectric term (  4r)
was chosen. The “united atom approximation” was used. The systems
were heated to 300 K with 5-K rise, every 100 steps per 6000 steps, by
randomly assigning velocities from the Gaussian distribution. After
heating, the system was allowed to equilibrate for 34 ps. The lengths of
the bonds involving the hydrogen atoms were constrained according to
the SHAKE algorithm, allowing an integration time step of 0.001 ps. A
disulfide bridge was imposed to form between Cys-107 (3.25) (in paren-
theses, the numbering from Ballesteros and Weinstein (Ref. 18) for the
amino acids in the helix-bundle is reported) and Cys-182 in E2. The
secondary structure of the seven helix-bundle was preserved by using
the nuclear Overhauser effect constraints. These constraints were ap-
plied between the backbone oxygen atoms of residue i and the backbone
nitrogen atom of residue i  4, excluding prolines. Different combina-
tions of intra-helix distance constraints were also probed. The non-
canonical -helical structure in the extracellular half of helix 7 was
preserved by nuclear Overhauser effect constraints. The structures
averaged over the 200 structures collected during the last 100 ps of the
equilibrated trajectories and minimized were comparatively analyzed.
One of the average arrangements obtained was then considered for
docking simulations.
Also for the human A2AR, the whole sequence was modeled (SWISS-
PROT entry P29274). Building of the C-tail (i.e. the 303–412 segment)
was primarily achieved by comparative modeling (14). Two different
models of this receptor portion were achieved: (a) model 1, obtained by
Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization 46743
using the domain A3 of transketolase (PDB entry 1trk; sequence 544–
680) as a template and (b) model 2, obtained by using the domain 2 of
the cytidine deaminase (PDB entry 1ctt; sequence 180–294) as a tem-
plate, according to the results of fold recognition (15). Indeed, both
1trkA3 and 1ctt02 domains, which share a three-layer () sandwich
architecture, were the top hits of the THREADER run, characterized by
comparable z-scores (i.e. 3.17 and 3.14, respectively). The agreement
between the secondary structures predicted on the A2AR C-tail se-
quence and that computed on the C-tail models in the average mini-
mized structures of the receptor is acceptable, especially for the C-tail
based upon 1ctt02. Three modified rhodopsin templates (PDB entry
1F88; Ref. 16) were built in which the segments 227–235, 240–246, and
321–348 were deleted and either model 1 or model 2 of the C-tail from
the human A2AR sequence was added. In particular, one template holds
“model 1 C-tail,” whereas the other two templates hold “model 2 C-tail,”
but in a slightly different orientation. Each of these templates was used
to generate 50 models according to alignment reported in Fig. 12 (avail-
able as supplementary material in the on-line version of this article).
-Helical restraints were applied to the amino acid stretches 198–209,
221–228, 224–227, and 299–306. The best A2AR models obtained from
each of the three MODELLER runs were subjected to refinement of I3
by means of MODELLER, leading to other three sets of structures.
From each of these three sets of structures, one model was finally
selected and subjected to automatic rotation of the side chains when in
bad conformation, leading to different input arrangements. For the
A2AR model holding the “model 1” C-tail and for that holding the
“model 2” C-tail, 19 and 17 different input structures were, respec-
tively, subjected to energy minimization and Molecular Dynamics sim-
ulations. The same computational protocol as that employed for the D2R
was followed. A disulfide bridge was imposed to form between Cys-77
(3.25) and Cys-159 in E2. The structures averaged over the 200 struc-
tures collected during the last 100 ps of the equilibrated trajectories and
minimized were then analyzed. Eleven average arrangements were
finally considered for docking simulations.
Computations: Rigid Body Docking Simulations—One selected aver-
age arrangement for the human D2R was subjected to rigid body dock-
ing simulations with 11 different average arrangements of the human
A2AR. Docking simulations were carried out by means of two different
rigid body docking programs, ZDOCK 2.1 (19) and ESCHER (20). De-
fault conditions were used. Each ZDOCK run provided 2000 solutions
filtered according to the shape complementarity score. On the other
hand, each ESCHER run produced 30,000 solutions that were then
filtered according to both shape and electrostatic complementarity, by
using bump and charge cutoffs of 200 and 200, respectively. The
filtered ZDOCK and ESCHER solutions were then subjected to a filter
made in-house that discharged all the solutions that violated the mem-
brane topology requirements. A few selected D2R-A2AR complexes, rep-
resentatives of the most populated docking solutions, were then sub-
jected to manual relief of the steric conflicts followed by energy
minimization.
RESULTS
Functionality of Modified A2ARs and D2Rs—The formation of
A2AR-D2R heterodimers was demonstrated by BRET and
FRET techniques in cells transfected with fusion proteins con-
sisting of each receptor and either a fluorescent protein (GFP2,
YFP) or Renilla luciferase (Rluc). Expression of fusion proteins
and or the chimeric D2R-D1R protein was assessed by Western
blot and immunocytochemistry (data not shown). The function-
ality of the receptor-Rluc, -GFP2, or -YFP constructs was as-
sessed by the determination of cAMP levels produced in trans-
fected cells in response to ligand binding. According to the
positive coupling of A2AR to the adenylyl cyclase, the A2AR
agonist CGS21680 properly induced cAMP accumulation in
cells transfected with A2AR-YFP or A2AR-Rluc (Fig. 1A). On the
other hand, in agreement with the inhibitory role of D2R on
adenylyl cyclase activity, the D2R agonist quinpirole was able
to reduce forskolin-induced cAMP levels in cells transfected
with either D2R-YFP or D2R-GFP2 (Fig. 1B).
FRET Experiments—FRET and BRET approaches have been
used in several studies to assess GPCR homo- and heterodimer-
ization as reviewed by Angers et al. (21). By using the FRET
approach with the D2R-GFP2 and A2AR-YFP pair, it was pos-
sible to confirm the heteromerization between A2AR and D2R
and to estimate the distance between the fluorophores. Using
the acceptor photobleaching technique and confocal microscopy
on cells expressing both receptors in the plasma membrane, a
direct interaction was demonstrated between A2AR and D2R
(Fig. 2). FRET efficiency was determined to be in the range of
23–25%. Similar FRET efficiencies were obtained using a flu-
orescence plate reader as described under “Experimental Pro-
cedures” (Fig. 3). The low FRET efficiency of a negative control
constituted by the pair D2R-GFP2 and CD4-YFP demonstrated
the specificity in the energy transfer between D2R-GFP2 and
A2AR-YFP (Fig. 3). Using the theoretical curve of FRET effi-
ciency correlated to the distance between the donor and accep-
tor fluorophores while assuming only a dimeric interaction, an
efficiency in the range of 23–25%, indicates that the distance
between fluorophores (GFP2 and YFP), both located at the C
terminus of either A2AR or D2R, is 6–6.5 nm (Fig. 4).
BRET Experiments—In BRET experiments, little attention
has been paid to the ratio of donor to acceptor molecules; thus,
the interpretation of the data has remained rather qualitative.
Indeed, the level of energy transfer detected for a given con-
centration of donor should increase with higher concentrations
of acceptor until all of the donor molecules are bound to an
acceptor molecule. This follows the theory that the energy
transfer will reach a plateau therefore giving rise to a satura-
tion curve. The maximum level reached will be a function of the
total number of dimers formed and of the distance between the
donor and acceptor while considering the relative orientation of
the proteins within the dimers. The concentration of acceptor,
giving 50% of the maximum energy transfer (BRET50), will
FIG. 1. Functionality test of receptors fused to GFP variants or
Renilla luciferase (Rluc). HEK-293T cells transiently transfected
with the corresponding constructs were stimulated with either 200 nM
CGS21680 for A2AR (panel A), or 10 M quinpirole in the presence of 10
M forskolin for D2R (panel B). A2AR induction of cAMP production is
presented as percentage over basal levels (100%). As D2R inhibits the
production of cAMP, results are presented as its ability to inhibit
forskolin induced cAMP production (100%). Results are a mean  S.D.
of four independent experiments performed in triplicate. One-way
ANOVA showed a significant increase of cAMP production with CGS
21680 with wild-type A2AR and the A2AR fused to Rluc or YFP. Simi-
larly, one-way ANOVA showed a significant decrease in forskolin-in-
duced cAMP production with quinpirole with wild-type D2R and the
D2R fused to GFP2 or YFP (post hoc Newman-Keuls test; p 	 0.05 in all
cases).
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reflect the relative affinity of an acceptor and a donor to
dimerize (22).
Here, we applied this theoretical framework to study A2AR
and D2R heteromerization by constructing a BRET saturation
curve in cells co-transfected with a constant amount of the
A2AR-Rluc construct while increasing concentrations of the
D2R-YFP plasmid. A positive BRET signal for the transfer of
energy between A2AR-Rluc and D2R-YFP was obtained (Fig. 5).
The BRET signal increased as a hyperbolic function of the
concentration of the YFP-fusion construct added (assessed by
the fluorescence emitted upon direct excitation at 480 nm)
reaching an asymptote. As the pair A2AR-Rluc and GABABR2-
YFP led to an undetectable BRET signal (Fig. 5), the hyperbolic
BRET signal found for the A2AR-Rluc-D2R-YFP indicates that
the interaction between A2AR and D2R is specific.
Energy transfer between closely located receptor molecules
can occur even in the absence of direct interaction (23). In fact,
receptors located within specific plasma membrane microdo-
mains, such as membrane rafts, may give rise to FRET or
BRET signals not caused by real heteromerization. Raft local-
ization of overexpressed membrane fluorescent proteins could
allow a close enough proximity (	10 nm) to permit the transfer
of energy. To explore this possibility, membrane rafts were
disrupted by cyclodextrin treatment, and BRET assays were
performed in these cells. As indicated in Fig. 3A, cyclodextrin
did not lead to any change in the BRET signal for A2AR-Rluc-
D2R-YFP. In addition, no change in the BRET signal was noted
when cells were repleted with cholesterol after cyclodextrin
treatment (Fig. 6A). The efficacy of the treatment was assessed
by cyclodextrin-mediated extracellular signal-regulated ki-
nase-1/2 phosphorylation, as indicated by Furuchi and Ander-
son (24). Raft disruption was also assessed by the redistribu-
tion of caveolin-1 from raft-enriched light fractions to heavier
fractions after sucrose gradient separation (Fig. 6B). Taken
together, this indicates that the energy transfer between A2AR-
Rluc and D2R-YFP is the result of the formation of true
heterodimers.
Stimulation with the A2AR agonist CGS21680 or the D2R
agonist quinpirole, individually or in combination, did not pro-
mote any consistent change in either maximal BRET (data not
shown) or BRET50 (Fig. 7). An analysis of the subcellular dis-
tribution of the fusion proteins indicated that the lack of ago-
FIG. 2. Imaging FRET efficiency of
the D2R-GFP2 and A2AR-YFP pair by
acceptor photo-bleaching. HEK-293T
cells were transiently transfected with
the plasmid DNA for the D2R-GFP2 and
A2AR-YFP constructs using a ratio of do-
nor to acceptor DNA of 1:2 and fixed 48 h
after transfection. Central panels are im-
ages of the D2R-GFP2 donor before (Do-
nor prebleach) and after (Donor post-
bleach) photo-bleaching of the A2AR-YFP
acceptor obtained in a central region of
the lowest plane of the cell by spectral
imaging and subsequent liner un-mixing
as described under “Experimental Proce-
dures.” The extent of the photo-bleaching
is shown in the bottom panels as a lack of
acceptor fluorescence in the selected re-
gion after photo-bleaching (Acceptor post-
bleach) with respect to the image of the
acceptor before photo-bleaching (Acceptor
prebleach). The top panels represent do-
nor un-quenching following acceptor pho-
to-bleaching as donor postbleach  donor
prebleach (subtraction) and a color repre-
sentation of the FRET efficiency (normal-
ized) calculated as indicated under “Ex-
perimental Procedures” and normalized
to a scale from 0 to 1.
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nist modulation of the BRET signal occurred in cells expressing
A2A-Rluc and D2R-YFP in the plasma membrane (Fig. 8). These
results indicate that receptor activation does not affect their
oligomerization state and that the heteromers are, most prob-
ably, constitutively pre-formed. However, one cannot exclude
the possibility that agonist stimulation may promote assembly/
disassembly cycles that do not affect the steady-state propor-
tion of receptors engaged in dimers.
To gain some insight into the putative heterodimer interface,
a chimeric D2R-D1R in which helices 5, 6, I3, and E3 of the D2R
have been swapped by the corresponding sequence from the
D1R (11) was used as a competitor in BRET experiments.
Although the wild-type D2R was able to decrease the BRET
signal between A2AR-Rluc and D2R-YFP, the D2R-D1R chi-
meric receptor failed to decrease the BRET signal even at high
amounts of competitor cDNA (Fig. 9). These results are in
agreement with previous studies, where we have shown that
A2AR does not modulate the agonist binding characteristics of
this chimeric D2R-D1R (25). This suggests somewhere in the
region of the D2R containing helices 5, 6, I3, and E3 of the D2R
lies a critical site necessary for the heteromerization with
A2AR.
Computational Experiments—Further insight into the D2R-
A2AR heterodimer interface was obtained by docking simula-
tions on theoretical models of D2R and A2AR. The whole se-
quences of both receptors were modeled, because dimerization
and/or oligomerization might also involve the cytosolic and/or
the extracellular domains as recently suggested for rhodopsin
(26). We are aware that structural errors might reside partic-
ularly in these receptor portions. Additionally, for this reason,
we have used nine different average minimized structures of
the A2AR, differing in the conformations of the intracellular
and extracellular domains as well as in the topology of the huge
FIG. 3. FRET efficiency of the D2R-GFP2 and A2AR-YFP pair by
sensitized emission in living cells. HEK-293T cells were transiently
transfected with the plasmid DNA corresponding to D2R-GFP2 (donor)
and A2AR-YFP (acceptor) proteins using a ratio of donor to acceptor
DNA of 1:2, or with the positive control plasmid GFP2-YFP. Fluores-
cence readings were performed 48 h after transfection as described
under “Experimental Procedures.” Linear un-mixing of the emission
signals was applied to the data (see “Experimental Procedures”), and
the results are shown as the sensitized emission of the acceptor when
the cells were excited at 400 nm. CD4-YFP was used as a negative
control. Data are the mean  S.D. of five independent experiments
performed in duplicate. One-way ANOVA followed by Newman-Keuls
test shows significant differences between GFP2-YF2 and D2R-
GFP2A2AR-YFP and between D2R-GFP2A2AR-YFP and D2R-
GFP2CD4-YFP (p 	 0.01 in all cases).
FIG. 4. FRET efficiencies related to the distance between the
fluorescent proteins. FRET efficiencies of the GFP2 and YFP pair
derived from their spectral properties were plotted as a function of the
distance between the fluorescent proteins as described by Zimmermann
et al. (12). Dotted lines show the relation between the determined FRET
efficiency for the D2R-GFP2-A2AR-YFP pair and the approximate dis-
tance between the fluorescent proteins in this pair.
FIG. 5. BRET saturation curve. BRET was measured in HEK-293T
cells co-expressing A2AR-Rluc and D2R-YFP (squares) or A2AR-Rluc and
GABABR2-YFP (triangles) constructs. Co-transfections were performed
with increasing amounts of plasmid DNA for the YFP construct
whereas the DNA for the Rluc construct was maintained constant. Both
fluorescence and luminescence of each sample were measured prior to
every experiment to confirm equal expression of Rluc while monitoring
the increase of YFP expression.
FIG. 6. -CD treatment. BRET experiments were performed in
HEK-293T cells co-transfected with the amount of plasmid DNA for the
A2AR-Rluc and D2R-YFP constructs to give BRET50. Cells were not
treated (Control) or treated with 2% -CD for 1 h (Depleted). Cholesterol
repletion was achieved by incubating depleted cells for 1 h with 0.4%
-CD and 16 mg/ml cholesterol (Repleted). No differences in BRET were
observed after depletion or repletion treatment (panel A) (analyzed with
one-way ANOVA). For immunoblotting of caveolin-1 in cells treated
with -CD (panel B), extracts from control and treated cells were
fractionated by a discontinuous sucrose gradient to obtain the light and
heavy membrane fractions. Caveolin-1 was detected by Western blot in
both membrane fractions. Densitometry of the bands was performed,
and results are expressed as the percentage of the total intensity.
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C-tail, to probe the effect of such structural differences on the
results of docking simulations. The A2AR structures include
four structures holding the “model 1 C-tail” (see “Experimen-
tal Procedures”) and seven structures holding the “model 2
C-tail.” Each of these structures has been docked with the
selected average minimized structure of D2R. Two different
rigid-body docking programs, ZDOCK (19) and ESCHER (20),
were employed. A total amount of 32,000 and 9400 filtered
solutions (see “Experimental Procedures”) was obtained by
means of different runs of ZDOCK 2.1 and ESCHER, respec-
tively. These solutions were subjected to an additional filter
that discharged those arrangements that significantly violate
the membrane topology requirements. In the majority of the
more realistic (i.e. dimers with lower interacting enthalpy)
docking solutions, the D2R portions that participate in the
heterodimer interface include the C-terminal half of helix 5, the
N-terminal portion of I3 that contains a solvent-exposed
stretch of positively charged amino acids (i.e. 217–220), helix 6,
helix 7, and the segment that corresponds to helix 8 of rhodop-
sin (16). Among these solutions, a highly populated one (popu-
lation 1, Fig. 10) is characterized by the following contacts: (a)
helix 5(D2R)-helix 4(A2AR) and I3N-term(D2R)-C-tailC-term-
(A2AR) and (b) helix 5C-term(D2R)-helix 3C-term(A2AR), helix
6(D2R)-helix 4(A2AR) and I3N-term(D2R)-C-tailC-term(A2AR);
helix 7(D2R) may also participate together with helix 6 in the
contacts with helix 4(A2AR). To estimate the putative interflu-
orophore distances in selected members of population 1, the
structures of GFP and YFP (PDB entries 2emn and 1huy,
respectively), have been approached to D2R and A2AR, respec-
tively, in selected dimmers, the first amino acid of the fluores-
cent proteins being close to the last amino acid of the receptors.
The distance between the C1 atoms of the GFP and YFP chro-
mophores in the different complexes ranges between 6 and 8
nm, very similar to that deduced from FRET experiments.
In a less populated solution (population 2, Fig. 10), almost
two different sets of contacts characterize the D2R-A2AR
dimers. The first set of contacts includes: (a) I2(D2R)-I2(A2AR),
(b) helix 4C-teminal half(D2R)-helix 3C-terminal half(A2AR), (c)
helix 4N-terminal half(D2R)-helix 5N-terminal half(A2AR), and (d)
helix 5(D2R)-helix 4(A2AR). The second set of contacts in-
cludes: (a) helix 3C-terminal half(D2R)-helix 4C-terminal half-
(A2AR), (b) helix 4N-terminal half(D2R)-helix 5N-terminal half-
(A2AR), (c) helix 5(D2R)-helix 4(A2AR), and (d) I3(D2R)-C-
tail(A2AR) (only a few contacts).
DISCUSSION
Adenosine-dopamine interactions play a very important role
in basal ganglia function and dysfunction. This is the result of
the existence of specific antagonistic interactions between dif-
ferent adenosine and dopamine receptor subtypes co-localized
in different neurons of the striatum, the main input structure
of the basal ganglia. Two subtypes of GABAergic efferent neu-
rons, the striatonigral and the striatopallidal neurons, consti-
tute more than 90% of the striatal neuronal population. The
interaction of A1Rs and D1Rs modulates the function of stria-
tonigral neurons, whereas the interactions of A2AR and D2R
modulates the function of striatopallidal neurons (5, 7, 8). The
existence of functional A1R-D1R and A2AR-D2R heteromeric
complexes has recently been demonstrated in mammalian cell
lines (10, 27). However, the techniques used in previously re-
ported data, including co-immunoprecipitation and confocal
laser microscopy co-localization studies, could not discard the
possibility of a third protein acting as scaffolding to bring the
two receptors together.
In the present work, we have used FRET and BRET tech-
niques to demonstrate that, in fact, A2AR and D2R form het-
eromers in living cells. This interaction was found to be specific
where no BRET or FRET signals were detected when other
receptors were assayed (see “Results”). The estimated distance
between the fluorophores fused to C-terminal tails of A2AR and
D2R resulted to be 6.3 nm. Receptor molecules with very close
proximity in small membrane microdomains can lead to arti-
factual BRET results, as with proteins targeted to cholesterol-
rich plasma membrane domains by lipid anchoring clusters in
rafts (23). This was ruled out by the unmodified BRET signal
between A2AR-Rluc and D2R-YFP in the presence of cyclodex-
FIG. 7. Effect of ligands on A2AR-D2R dimerization. BRET meas-
urements were performed after 1 h of treatment with 200 nM A2AR
agonist CGS21680 (CGS), 10 M D2R agonist quinpirole, or both ligands
simultaneously in HEK-293T cells co-transfected with the A2AR-Rluc-
D2R-YFP pair at the BRET50 ratio. Data are mean  S.D. of three
independent experiments. Results are expressed as the percentage of
the BRET50 value of untreated (control) cells. No significant differences
were observed between the three different groups (one-way ANOVA).
FIG. 8. Subcellular distribution of A2AR-Rluc and D2R-YFP
constructs. Lysates of co-transfected HEK-293T cells as described in
Fig. 7 were applied and separated on a discontinuous sucrose gradient.
Fractions were subsequently analyzed for luminescence (top panel) and
by immunoblotting (bottom panel). As a result of high levels of fluores-
cence in fractions with large concentrations of sucrose, the distribution
of D2R-YFP was analyzed by Western blot with an anti-GFP antibody.
Fractions rich in plasma membrane and ER were detected by Western
blot using either NaK-ATPase or calnexin antibodies, respectively.
FIG. 9. BRET competition. HEK-293T cells were transfected with
the appropriate amount of plasmid DNA for the A2AR-Rluc and D2R-
YFP constructs corresponding to the previously determined BRET50
(control) and with increasing amounts of D2R cDNA (gray bars) or the
cDNA of the dopamine D2R-D1R chimera (black bars). The BRET ratio
was determined and values are expressed as a percentage of the control.
Data are the mean  S.D. of five experiments in duplicate. One-way
ANOVA (with post-hoc Newman-Keuls comparisons) shows significant
BRET competition with 12.5 and 15 g of D2R cDNA (p 	 0.001 in both
cases) and no significant differences with 12.5 or 15 g of D2R-D1R
cDNA.
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trin, which disrupts rafts and prevents the eventual accumu-
lation of receptors in these structures (Fig. 6).
Homomerization and heteromerization of GPCRs have been
suggested to involve different receptor domains. The C-termi-
nal tail of the GABA receptors is involved in GABABR1-GAB-
ABR2 heteromerization by a coiled-coil interaction (28, 29).
X-ray studies performed with the metabotropic glutamate re-
ceptor mGlu1R have shown that its extracellular N-terminal
ligand-binding region forms disulfide-linked homodimers (30).
There is also evidence for the transmembrane domains in me-
diating the formation of homo- or heterodimers (for review, see
Ref. 1). The sixth and seventh helices of D2R have been impli-
cated in its homodimerization, because synthesized peptides
encoding sequences in these regions inhibit dimer formation
(31). Furthermore, Guo et al. (32) have recently reported that
D2R homodimers are stabilized by cross-linking through a cys-
teine residue located at the extracellular end of helix 4. The
present results using the previously characterized chimeric
D2R-D1R containing helices 5 and 6, I3, and E3 of the dopamine
D1R (9), demonstrate that these portions of the D2R are directly
involved in the formation of A2AR-D2R heteromers. Thus, dif-
fering from the wild-type D2R, the chimeric D2R-D1R was not
able to compete for the specific BRET between A2AR-Rluc
and D2R-YFP.
To gain insight into the potential D2R-A2AR heterodimer
interfaces, rigid-body docking simulations have been done be-
tween an average minimized structure of D2R and nine differ-
ent average minimized structures of A2AR. From docking sim-
ulations two sets of dimers sharing (within each set) similar
interdimer interfaces have been obtained (population 1 and
population 2, see Fig. 10). In particular, in the most populated
one (population 1), helix 5 and/or helix 6 and the N-terminal
portion of I3 from D2R approach helix 4 and the C-terminal
portion of the C-tail from the A2AR, respectively. Helix 7(D2R)
may also participate together with helix 6 in the contacts with
helix 4(A2AR) (Fig. 10, left side). The interface contacts in
population 1 are consistent with the results of BRET experi-
ments done in this work on the chimeric D2R-D1R and A2AR.
Population 2 has a reduced number of structures if compared
with population 1. However, structures in population 2 display
high docking scores and resemble the intradimer contact model
proposed for rhodopsin (26).
The analysis of the BRET signal in A2AR-D2R-expressing
cells indicated that the activation of A2AR or D2R by their
corresponding agonist did not affect the degree of heteromer-
ization. Similar results were obtained when the two agonists
were used simultaneously (Fig. 7). The lack of modulation by
agonists has also been reported for other homo- and het-
erodimeric partners (3, 33, 34). In carefully controlled BRET
studies, it has been demonstrated that a number of heteromer-
izing receptors are pre-assembled in the ER and the dimers
that reach the plasma membrane are not affected, in terms of
the degree of dimerization, after receptor activation by their
corresponding ligands (33–36). In contrast to this recently re-
ported data, detailed studies by Patel et al. (37) in stable
CHO-K1 cells expressing somatostatin receptors suggest that
the receptors are monomeric in their basal state and oligomer-
ize only upon agonist activation. For the somatostatin receptor
subtype R5, the same authors report that ligand-induced ho-
momerization extends beyond dimers to higher order oligomers
(39). For our experimental data, the unchanged BRET signal
reported in cells treated with agonists is not necessarily in
contradiction to the known clustering of these receptors when
they are activated by agonists. In fact, the A2AR agonist
CGS21680 leads to the clustering of A2AR receptors in neuro-
blastoma SH-SY5Y cells or in primary neuronal cell cultures,
and similar clustering occurs with D2R receptors when D2R-
expressing cells are treated with the D2R agonist quinpirole
(10). It should also be noted that co-clustering of A2AR and D2R
occurs when either agonist is added, alone or simultaneously,
to cells co-expressing both receptors (10). Taken together these
results indicate that A2AR or D2R agonists lead to the reorga-
nization of receptors within the plasma membrane while not
affecting their degree of heterodimerization. Considering the
FIG. 10. Examples of the D2R-A2AR
heterodimers belonging to popula-
tion 1 (top and bottom left) and to
population 2 (top and bottom right).
In the top views, the helix bundles are
seen in a direction parallel to the mem-
brane surface, the intracellular side being
at the top. In the bottom views, the helix
bundles are seen from the intracellular
side in a direction almost perpendicular
to the membrane surface. Helices 1, 2, 3,
4, 5, 6, and 7 are, respectively, blue, or-
ange, green, pink, yellow, cyan, and violet.
The amino acid stretch corresponding to
helix 8 of rhodopsin is violet as well. The
extracellular domains are gray, whereas
the intracellular loops 1, 2 and 3 and the
C-tail (C-term) are, respectively, light
green, white, purple, and red.
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data, it appears as if ligand-induced activation of the receptors
leads to target pre-existing A2AR-D2R heterodimers to mem-
brane microdomains. Ligand modulation of heteromers may
also be dependent upon the nature of the receptors involved
and their level of expression. It should not be ruled out that
other factors might also contribute to this modulation. Further
research is required to understand whether ligand regulation
is dependent on the particular expression of scaffold or chap-
erone proteins in cell models where ligand modulation of re-
ceptor oligomerization is studied.
Receptor-receptor heteromerization serves a variety of pur-
poses in receptor function. For instance, assembly of het-
erodimers is required for targeting GABAB receptors to the cell
surface (38). GABABR1-GABABR2 heterodimerization is neces-
sary for GABAB receptor signaling, because one of the receptors
within the heterodimer binds the ligand whereas the other is
linked to the signaling machinery. Moreover, GABABR2 is re-
quired to provide high affinity for agonists to the GABABR1
subunit (39). We have previously postulated that heterodimer-
ization may be necessary for intramembrane receptor-receptor
interactions, where the stimulation of one receptor changes the
binding characteristics of another receptor in tissue or cell
membrane preparations (5, 40–42). An intramembrane A2AR-
D2R antagonistic interaction has been repeatedly demon-
strated in both rat and human striatum as well as in trans-
fected mammalian cell lines, where the stimulation of A2AR
decreases the affinity of D2R receptor for agonists (9, 43–47). In
CHO-transfected cells, the A2AR agonist CGS 21680 decreased
the affinity of the D2R but not of the chimeric D2R-D1R for
tritiated dopamine (25). Taken together with the above-men-
tioned results, this strongly suggests that the intramembrane
A2AR-D2R interaction depends on the heteromerization be-
tween A2AR and D2R. It is very probable that the loss of affinity
to dopamine binding of the D2R when the A2AR is activated is
a result of conformational changes transmitted through the
heteromeric interaction. Interestingly, there is an increase in
the agonist binding affinity for D2R with an enhancement of G
protein and effector coupling to adenylyl cyclase when the D2R
and somatostatin SSTR5 receptors heteromerize in response to
agonist treatment (48). Therefore, the increase or decrease in
the affinity of agonist binding to D2R would depend on the
nature of the heteromeric partner; SSTR5 receptors leading to
an increase in its affinity (i.e. synergy) and A2AR leading to a
decrease (i.e. antagonism). This and other potential roles of the
A2AR-D2R heteromers are important to fully understand the
molecular basis of the adenosine-dopamine antagonism within
the central nervous system, thus allowing for the design of
novel strategies to combat basal ganglia disorders (like Parkin-
son’s disease), schizophrenia, and drug addiction.
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